

|
| N-Ethyl-N-methylcarbamic Acid 3-[(S)-1-(Dimethylamino)ethyl]phenyl Ester L-Tartrate |
¡Ø ÈÇиí : Rivastigmine tartrate, 98% (HPLC)
¡Ø µî±Þ : APIs and Bioactives > AChR Agonists, Alzheimers
¡Ø ÆÇ¸Å Æ÷Àå´ÜÀ§ : 100mg , 1g , 5g
¡Ø ÈÇÐ½Ä : C14H22N2O2.C4H6O6
¡Ø CAS # : [129101-54-8]
|
| IDENTITY |
|
| CAS Registry #: |
[129101-54-8] |
| MDL Number: |
MFCD03700731 |
| MF: |
C14H22N2O2.C4H6O6 |
| MW: |
400.4235 | |
| SPECIFICATIONS & PROPERTIES |
|
| Purity: |
98% (HPLC) |
| Available Spectra: |
NMR, LCMS, HPLC |
| Physical Form: |
White to off-white crystalline powder |
| Melting Point: |
115-128¡ÆC |
| Optical Rotation: |
+4.7¡Æ (c=5, EtOH) |
| Long-Term Storage: |
Store at room temperature |
| Shipping: |
Regulated for Shipping |
| UN #: |
2811 |
| Hazard Class: |
6.1 |
| Packing Group: |
III | | |
BIOLOGICAL INFO |
|
| Application(s): |
Cholinesterase inhibitor | REVIEW Rivastigmine is a carbamate derivative that is structurally related to physostigmine, but not to donepezil and tacrine. The precise mechanism of rivastigmine has not been fully determined, but it is suggested that rivastigmine binds reversibly with and inactivates chlolinesterase (eg. acetylcholinesterase, butyrylcholinesterase), preventing the hydrolysis of acetycholine, and thus leading to an increased concentration of acetylcholine at cholinergic synapses. The anticholinesterase activity of rivastigmine is relatively specific for brain acetylcholinesterase and butyrylcholinesterase compared with those in peripheral tissues.
REFERENCES
[1] |
Camps P, Munoz-Torrero D: Cholinergic drugs in pharmacotherapy of Alzheimers disease. Mini Rev Med Chem. 2002 Feb;2(1):11-25. |
| [2] |
Rosler M, Anand R, Cicin-Sain A, Gauthier S, Agid Y, Dal-Bianco P, Stahelin HB, Hartman R, Gharabawi M: Efficacy and safety of rivastigmine in patients with Alzheimers disease: international randomised controlled trial. BMJ. 1999 Mar 6;318(7184):633-8. |
| [3] |
Finkel SI: Effects of rivastigmine on behavioral and psychological symptoms of dementia in Alzheimers disease. Clin Ther. 2004 Jul;26(7):980-90. |
| [4] |
Rosler M, Retz W, Retz-Junginger P, Dennler HJ: Effects of two-year treatment with the cholinesterase inhibitor rivastigmine on behavioural symptoms in Alzheimers disease. Behav Neurol. 1998;11(4):211-216. | Risk Description(s)
| R36/37/38: |
Irritating to eyes, respiratory system and skin | Safety Description(s)
| S24/25: |
Avoid contact with skin and eyes. | |


°í¾×°áÁ¦ÀÇ °æ¿ì ¾ÈÀüÀ» À§ÇØ Ä«µå»ç¿¡¼ È®ÀÎÀüȸ¦ µå¸± ¼öµµ ÀÖ½À´Ï´Ù. È®ÀΰúÁ¤¿¡¼ µµ³ Ä«µåÀÇ »ç¿ëÀ̳ª ŸÀÎ ¸íÀÇÀÇ ÁÖ¹®µî Á¤»óÀûÀÎ ÁÖ¹®ÀÌ ¾Æ´Ï¶ó°í ÆÇ´ÜµÉ °æ¿ì ÀÓÀÇ·Î ÁÖ¹®À» º¸·ù ¶Ç´Â Ãë¼ÒÇÒ ¼ö ÀÖ½À´Ï´Ù.
¹«ÅëÀå ÀÔ±ÝÀº »óǰ ±¸¸Å ´ë±ÝÀº PC¹ðÅ·, ÀÎÅͳݹðÅ·, ÅÚ·¹¹ðÅ· ȤÀº °¡±î¿î ÀºÇà¿¡¼ Á÷Á¢ ÀÔ±ÝÇÏ½Ã¸é µË´Ï´Ù.
ÁÖ¹®½Ã ÀÔ·ÂÇÑ ÀÔ±ÝÀÚ¸í°ú ½ÇÁ¦ÀÔ±ÝÀÚÀÇ ¼º¸íÀÌ ¹Ýµå½Ã ÀÏÄ¡ÇÏ¿©¾ß Çϸç, 7ÀÏ À̳»·Î ÀÔ±ÝÀ» ÇÏ¼Å¾ß Çϸç ÀԱݵÇÁö ¾ÊÀº ÁÖ¹®Àº ÀÚµ¿Ãë¼Ò µË´Ï´Ù.
¹è¼Û ¹æ¹ý : ÅÃ¹è ¹× Á÷³³
¹è¼Û Áö¿ª : Àü±¹
¹è¼Û ºñ¿ë : ÃÑ ±¸¸Å ºñ¿ëÀÌ £Ü100,000 (VATº°µµ) ¹Ì¸¸ÀÏ °æ¿ì ÂøºÒ·Î ¹ß¼Û
¹è¼Û ±â°£ : ±¹»êǰ (3~7ÀÏ), ¼öÀÔǰ (7~14ÀÏ)
¹è¼Û ¾È³»
- »ê°£º®Áö³ª µµ¼Áö¹æÀº º°µµÀÇ Ãß°¡±Ý¾×À» ÁöºÒÇÏ¼Å¾ß ÇÏ´Â °æ¿ì°¡ ÀÖ½À´Ï´Ù.
°í°´´Ô²²¼ ÁÖ¹®ÇϽŠ»óǰÀº ÀÔ±Ý È®ÀÎÈÄ ¹è¼ÛÇØ µå¸³´Ï´Ù. ´Ù¸¸, »óǰÁ¾·ù¿¡ µû¶ó¼ »óǰÀÇ ¹è¼ÛÀÌ ´Ù¼Ò Áö¿¬µÉ ¼ö ÀÖ½À´Ï´Ù.


±³È¯ ¹× ¹ÝǰÀÌ °¡´ÉÇÑ °æ¿ì
- »óǰÀ» °ø±Þ ¹ÞÀ¸½Å ³¯·ÎºÎÅÍ 7ÀÏÀ̳»
±³È¯ ¹× ¹ÝǰÀÌ ºÒ°¡´ÉÇÑ °æ¿ì
- °í°´´ÔÀÇ Ã¥ÀÓ ÀÖ´Â »çÀ¯·Î »óǰµîÀÌ ¸ê½Ç ¶Ç´Â ÈÑ¼ÕµÈ °æ¿ì
- Æ÷ÀåÀ» °³ºÀÇÏ¿´°Å³ª Æ÷ÀåÀÌ ÈÑ¼ÕµÇ¾î »óǰ°¡Ä¡°¡ »ó½ÇµÈ °æ¿ì
- ½Ã°£ÀÇ °æ°ú¿¡ ÀÇÇÏ¿© ÀçÆÇ¸Å°¡ °ï¶õÇÒ Á¤µµ·Î »óǰµîÀÇ °¡Ä¡°¡ ÇöÀúÈ÷ °¨¼ÒÇÑ °æ¿ì
- ¿Âµµ°ü¸®Ç° ¹× ¼öÀÔǰÀº ¹ÝǰÀÌ ºÒ°¡´ÉÇÕ´Ï´Ù.
¡Ø ÁÖ¹® Ãë¼Ò ¹× ¹ÝǰÀ¸·Î ȯºÒÀ» ¿äûÇÏ½Ç °æ¿ì¿¡´Â E-mail(info@syinnovation.co.kr) »ó´ã¼ºñ½º³ª °í°´¸¸Á·¼¾ÅÍ(070-4829-4101)¸¦ ÅëÇØ ¿äûÇϽøé Ä£ÀýÇÏ°Ô Ã³¸®ÇØ µå¸®°Ú½À´Ï´Ù.